Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kava Pharmacokinetics
NCT03843502Phase 1Completed
- Sponsor
- University of Florida
- Start
- Feb 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kava in generalized anxiety disorder (GAD), sponsored by University of Florida. Primary endpoint: Time to Maximum Concentration at 12 hours. Started Feb 2020; status: completed.
02
Drugs
kava
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT03843502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843502.